Translational research takes place worldwide in several sequential phases. Nuclear medicine specialist Professor Philipp Backhaus is primarily involved in the early phases of translation, specialising in the imaging and therapy of tumours and inflammation. For several months, his team has been contributing to the development of the drug “OncoACP3”, which aims to improve the examination of prostate cancer.
